Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：136頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2014’, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ankylosing Spondylitis (Bekhterev's Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ankylosing Spondylitis (Bekhterev's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2014’, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ankylosing Spondylitis (Bekhterev's Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ankylosing Spondylitis (Bekhterev's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Ankylosing Spondylitis (Bekhterev's Disease) Overview 10
Therapeutics Development 11
Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Overview 11
Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis 12
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics under Development by Companies 13
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Ankylosing Spondylitis (Bekhterev's Disease) - Products under Development by Companies 20
Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development 22
Alcon, Inc. 22
Boehringer Ingelheim GmbH 23
Amgen Inc. 24
Eli Lilly and Company 25
Merck & Co., Inc. 26
Piramal Enterprises Limited 27
Celltrion, Inc. 28
Biocon Limited 29
Pfizer Inc. 30
Sandoz Inc. 31
Celgene Corporation 32
Panacea Biotec Limited 33
Viropro Inc. 34
Avesthagen Limited 35
Shanghai Celgen Bio-Pharmaceutical Co., Ltd. 36
Biosidus S.A. 37
Genor BioPharma Co., Ltd. 38
Aprogen, Inc. 39
Inbiopro Solutions Pvt. Ltd. 40
Curaxys, S.L. 41
Innovent Biologics, Inc. 42
PanPharmaceuticals USA, Inc. 43
Epirus Biopharmaceuticals, Inc. 44
AlphaMab Co., Ltd 45
Pharmapraxis 46
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Target 48
Assessment by Mechanism of Action 51
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
infliximab biosimilar - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
infliximab biosimilar - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ixekizumab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
apremilast - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
secukinumab - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
etoricoxib - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
infliximab biosimilar - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
adalimumab biosimilar - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
tofacitinib - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
BI-655066 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
infliximab biosimilar - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
infliximab biosimilar - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
adalimumab biosimilar - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
adalimumab biosimilar - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
P-979 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
etanercept biosimilar - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
adalimumab biosimilar - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
etanercept biosimilar - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
etanercept biosimilar - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
adalimumab biosimilar - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
adalimumab biosimilar - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
etanercept biosimilar - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
adalimumab biosimilar - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
IBI-303 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
ND-007 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
infliximab biosimilar - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
etanercept biosimilar - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
adalimumab biosimilar - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
INV-17 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
IBPM-005-IX - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
IBPM-004-AM - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
etanercept biosimilar - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
adalimumab biosimilar - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
infliximab biosmiliar - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
etanercept biosimilar - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
infliximab biosimilar - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
etanercept biosimilar - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
adalimumab biosimilar - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Ankylosing Spondylitis (Bekhterev's Disease) - Recent Pipeline Updates 104
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects 124
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products 125
Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones 126
Featured News & Press Releases 126
Oct 18, 2013: Cimzia Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis 126
Sep 11, 2013: Hospira’s Inflectra the first biosimilar monoclonal antibody to be approved in Europe 127
Sep 05, 2013: Horizon Pharma Announces Sanofi Compiegne as Additional Manufacturing Site for DUEXIS 129
Aug 22, 2013: Horizon Pharma Announces Settlement of DUEXIS Patent Litigation With Par Pharmaceutical 129
Jul 24, 2013: U.S. FDA Arthritis Advisory Committee Votes On Cimzia For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis 130
Jun 27, 2013: Celltrion Healthcare Receives CHMP Positive Opinion For Remsima 131
May 31, 2013: Celltrion Provides Update On CT-P13 EU Approval Process 133
Mar 26, 2013: Celltrion Signs KRW88 Billion Contract With Celltrion Healthcare 133
Mar 07, 2013: Horizon Pharma Receives Marketing Authorization For Duexis From UK Medicines And Healthcare Products Regulatory Agency 133
Dec 21, 2012: Horizon Pharma To Receive UK Medicines And MHRA Approval For Duexis 134
Appendix 135
Methodology 135
Coverage 135
Secondary Research 135
Primary Research 135
Expert Panel Validation 135
Contact Us 136
Disclaimer 136
List of Tables
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2014 11
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Comparative Analysis by Unknown Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Development by Companies, H1 2014 (Contd..1) 21
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Alcon, Inc., H1 2014 22
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Boehringer Ingelheim GmbH, H1 2014 23
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Amgen Inc., H1 2014 24
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Eli Lilly and Company, H1 2014 25
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Merck & Co., Inc., H1 2014 26
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Piramal Enterprises Limited, H1 2014 27
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celltrion, Inc., H1 2014 28
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Limited, H1 2014 29
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Pfizer Inc., H1 2014 30
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz Inc., H1 2014 31
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celgene Corporation, H1 2014 32
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Panacea Biotec Limited, H1 2014 33
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Viropro Inc., H1 2014 34
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Avesthagen Limited, H1 2014 35
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H1 2014 36
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biosidus S.A., H1 2014 37
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Genor BioPharma Co., Ltd., H1 2014 38
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Aprogen, Inc., H1 2014 39
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 40
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Curaxys, S.L., H1 2014 41
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Innovent Biologics, Inc., H1 2014 42
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by PanPharmaceuticals USA, Inc., H1 2014 43
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2014 44
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AlphaMab Co., Ltd, H1 2014 45
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Pharmapraxis, H1 2014 46
Assessment by Monotherapy Products, H1 2014 47
Number of Products by Stage and Target, H1 2014 50
Number of Products by Stage and Mechanism of Action, H1 2014 53
Number of Products by Stage and Route of Administration, H1 2014 55
Number of Products by Stage and Molecule Type, H1 2014 57
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics - Recent Pipeline Updates, H1 2014 104
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H1 2014 124
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H1 2014 125
List of Figures
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2014 11
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 47
Number of Products by Top 10 Target, H1 2014 48
Number of Products by Stage and Top 10 Target, H1 2014 49
Number of Products by Top 10 Mechanism of Action, H1 2014 51
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 52
Number of Products by Top 10 Route of Administration, H1 2014 54
Number of Products by Stage and Top 10 Route of Administration, H1 2014 55
Number of Products by Top 10 Molecule Type, H1 2014 56
Number of Products by Stage and Top 10 Molecule Type, H1 2014 57
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Ankylosing Spondylitis (Bekhterev's Disease) Overview 10
Therapeutics Development 11
Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Overview 11
Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis 12
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics under Development by Companies 13
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Ankylosing Spondylitis (Bekhterev's Disease) - Products under Development by Companies 20
Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development 22
Alcon, Inc. 22
Boehringer Ingelheim GmbH 23
Amgen Inc. 24
Eli Lilly and Company 25
Merck & Co., Inc. 26
Piramal Enterprises Limited 27
Celltrion, Inc. 28
Biocon Limited 29
Pfizer Inc. 30
Sandoz Inc. 31
Celgene Corporation 32
Panacea Biotec Limited 33
Viropro Inc. 34
Avesthagen Limited 35
Shanghai Celgen Bio-Pharmaceutical Co., Ltd. 36
Biosidus S.A. 37
Genor BioPharma Co., Ltd. 38
Aprogen, Inc. 39
Inbiopro Solutions Pvt. Ltd. 40
Curaxys, S.L. 41
Innovent Biologics, Inc. 42
PanPharmaceuticals USA, Inc. 43
Epirus Biopharmaceuticals, Inc. 44
AlphaMab Co., Ltd 45
Pharmapraxis 46
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Target 48
Assessment by Mechanism of Action 51
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
infliximab biosimilar - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
infliximab biosimilar - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ixekizumab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
apremilast - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
secukinumab - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
etoricoxib - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
infliximab biosimilar - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
adalimumab biosimilar - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
tofacitinib - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
BI-655066 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
infliximab biosimilar - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
infliximab biosimilar - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
adalimumab biosimilar - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
adalimumab biosimilar - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
P-979 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
etanercept biosimilar - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
adalimumab biosimilar - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
etanercept biosimilar - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
etanercept biosimilar - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
adalimumab biosimilar - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
adalimumab biosimilar - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
etanercept biosimilar - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
adalimumab biosimilar - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
IBI-303 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
ND-007 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
infliximab biosimilar - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
etanercept biosimilar - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
adalimumab biosimilar - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
INV-17 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
IBPM-005-IX - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
IBPM-004-AM - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
etanercept biosimilar - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
adalimumab biosimilar - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
infliximab biosmiliar - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
etanercept biosimilar - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
infliximab biosimilar - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
etanercept biosimilar - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
adalimumab biosimilar - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Ankylosing Spondylitis (Bekhterev's Disease) - Recent Pipeline Updates 104
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects 124
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products 125
Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones 126
Featured News & Press Releases 126
Oct 18, 2013: Cimzia Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis 126
Sep 11, 2013: Hospira’s Inflectra the first biosimilar monoclonal antibody to be approved in Europe 127
Sep 05, 2013: Horizon Pharma Announces Sanofi Compiegne as Additional Manufacturing Site for DUEXIS 129
Aug 22, 2013: Horizon Pharma Announces Settlement of DUEXIS Patent Litigation With Par Pharmaceutical 129
Jul 24, 2013: U.S. FDA Arthritis Advisory Committee Votes On Cimzia For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis 130
Jun 27, 2013: Celltrion Healthcare Receives CHMP Positive Opinion For Remsima 131
May 31, 2013: Celltrion Provides Update On CT-P13 EU Approval Process 133
Mar 26, 2013: Celltrion Signs KRW88 Billion Contract With Celltrion Healthcare 133
Mar 07, 2013: Horizon Pharma Receives Marketing Authorization For Duexis From UK Medicines And Healthcare Products Regulatory Agency 133
Dec 21, 2012: Horizon Pharma To Receive UK Medicines And MHRA Approval For Duexis 134
Appendix 135
Methodology 135
Coverage 135
Secondary Research 135
Primary Research 135
Expert Panel Validation 135
Contact Us 136
Disclaimer 136
List of Tables
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2014 11
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Comparative Analysis by Unknown Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Development by Companies, H1 2014 (Contd..1) 21
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Alcon, Inc., H1 2014 22
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Boehringer Ingelheim GmbH, H1 2014 23
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Amgen Inc., H1 2014 24
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Eli Lilly and Company, H1 2014 25
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Merck & Co., Inc., H1 2014 26
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Piramal Enterprises Limited, H1 2014 27
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celltrion, Inc., H1 2014 28
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Limited, H1 2014 29
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Pfizer Inc., H1 2014 30
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz Inc., H1 2014 31
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celgene Corporation, H1 2014 32
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Panacea Biotec Limited, H1 2014 33
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Viropro Inc., H1 2014 34
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Avesthagen Limited, H1 2014 35
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H1 2014 36
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biosidus S.A., H1 2014 37
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Genor BioPharma Co., Ltd., H1 2014 38
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Aprogen, Inc., H1 2014 39
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 40
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Curaxys, S.L., H1 2014 41
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Innovent Biologics, Inc., H1 2014 42
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by PanPharmaceuticals USA, Inc., H1 2014 43
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2014 44
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AlphaMab Co., Ltd, H1 2014 45
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Pharmapraxis, H1 2014 46
Assessment by Monotherapy Products, H1 2014 47
Number of Products by Stage and Target, H1 2014 50
Number of Products by Stage and Mechanism of Action, H1 2014 53
Number of Products by Stage and Route of Administration, H1 2014 55
Number of Products by Stage and Molecule Type, H1 2014 57
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics - Recent Pipeline Updates, H1 2014 104
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H1 2014 124
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H1 2014 125
List of Figures
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2014 11
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 47
Number of Products by Top 10 Target, H1 2014 48
Number of Products by Stage and Top 10 Target, H1 2014 49
Number of Products by Top 10 Mechanism of Action, H1 2014 51
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 52
Number of Products by Top 10 Route of Administration, H1 2014 54
Number of Products by Stage and Top 10 Route of Administration, H1 2014 55
Number of Products by Top 10 Molecule Type, H1 2014 56
Number of Products by Stage and Top 10 Molecule Type, H1 2014 57
